NASDAQ:INAB - Nasdaq - US45674E1091 - Common Stock - Currency: USD
0.169
0 (-1.74%)
The current stock price of INAB is 0.169 USD. In the past month the price decreased by -2.14%. In the past year, price decreased by -83.1%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19 | 345.13B | ||
AMGN | AMGEN INC | 14.68 | 156.41B | ||
GILD | GILEAD SCIENCES INC | 13.76 | 132.82B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1756.9 | 130.98B | ||
REGN | REGENERON PHARMACEUTICALS | 13.51 | 65.46B | ||
ARGX | ARGENX SE - ADR | 339.55 | 39.39B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.24B | ||
ONC | BEIGENE LTD-ADR | N/A | 28.00B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.04B | ||
NTRA | NATERA INC | N/A | 20.40B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
BIIB | BIOGEN INC | 7.35 | 17.72B |
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-11-12. The firm is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
IN8BIO INC
Empire State Building, 350 5Th Avenue, Suite 5330
New York City NEW YORK US
CEO: William Ho
Employees: 39
Company Website: https://www.in8bio.com
Investor Relations: https://investors.in8bio.com/
Phone: 16466006438
The current stock price of INAB is 0.169 USD. The price decreased by -1.74% in the last trading session.
The exchange symbol of IN8BIO INC is INAB and it is listed on the Nasdaq exchange.
INAB stock is listed on the Nasdaq exchange.
10 analysts have analysed INAB and the average price target is 2.66 USD. This implies a price increase of 1476.78% is expected in the next year compared to the current price of 0.169. Check the IN8BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
IN8BIO INC (INAB) has a market capitalization of 13.73M USD. This makes INAB a Nano Cap stock.
IN8BIO INC (INAB) currently has 39 employees.
IN8BIO INC (INAB) has a resistance level at 0.18. Check the full technical report for a detailed analysis of INAB support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
INAB does not pay a dividend.
IN8BIO INC (INAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.58).
The outstanding short interest for IN8BIO INC (INAB) is 0.66% of its float. Check the ownership tab for more information on the INAB short interest.
ChartMill assigns a fundamental rating of 1 / 10 to INAB. INAB may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months INAB reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 42.57% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -145.33% | ||
ROE | -210.23% | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 82% to INAB. The Buy consensus is the average rating of analysts ratings from 10 analysts.